SCHEMBL538654

SCHEMBL538654

COc1ccc(CN2CCc3n[nH]c4nc(NCCN5CCOCC5)nc2c34)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 2/20 0.46
MTOR P42345 2/20 0.46
MAPK1 P28482 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
BACE1 P56817 2/20 0.43
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.43
EGFR P00533 1/20 0.42
LMNA P02545 3/20 0.42
RAB9A P51151 2/20 0.42
PDE5A O76074 2/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
TSHR P16473 2/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
PKM P14618 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814373 0.95 PIK3CA (0.45) PIK3CAMTORMAPK1SMN1; SMN2BACE1
SCHEMBL14405862 0.91 TLR9 (0.41) PIK3CAMTORMEN1KMT2AACP1
SCHEMBL2812166 0.88 LMNA (0.55) PIK3CAMTORBACE1HPGDLMNA
SCHEMBL2809862 0.85 PIK3CA (0.47) PIK3CAMTORMAPK1SMN1; SMN2BACE1
SCHEMBL2814500 0.83 LMNA (0.48) MAPK1SMN1; SMN2HPGDMAPTLMNA
SCHEMBL2810268 0.83 CLPP (0.42) SMN1; SMN2MAPTKDM4EALDH1A1KMT2A
SCHEMBL2813934 0.83 CLPP (0.42) SMN1; SMN2MAPTKDM4EALDH1A1KMT2A
SCHEMBL2812929 0.83 CLK4 (0.43) MAPK1SMN1; SMN2HPGDMAPTLMNA
SCHEMBL537583 0.83 CLPP (0.49) SMN1; SMN2BACE1HPGDMAPTKDM4E
SCHEMBL2809363 0.82 GRK6 (0.42) MAPTKDM4EALDH1A1POLBACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2414359-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP claimed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO claimed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 PIK3CA 74/4885MTOR 351/4885MAPK1 1997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.